Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.62 +1.3%	$1.62	$0.99 ▼ $6.26	$146.34M	2.74	1.33 million shs	797,296 shs
FHTX Foghorn Therapeutics	$5.56 +10.3%	$5.26	$2.94 ▼ $10.25	$284.91M	3.05	102,469 shs	160,364 shs
LFCR Lifecore Biomedical	$7.60 +5.3%	$7.58	$3.68 ▼ $8.85	$270.08M	0.65	116,304 shs	119,681 shs
SGMT Sagimet Biosciences	$7.11 -3.3%	$8.67	$1.73 ▼ $11.41	$225.46M	3.37	745,858 shs	479,109 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	+1.27%	-3.03%	+1.27%	-8.57%	-72.88%
FHTX Foghorn Therapeutics	-4.18%	-1.95%	-20.50%	+21.74%	-31.89%
LFCR Lifecore Biomedical	-0.28%	-2.70%	-2.96%	+7.44%	+26.44%
SGMT Sagimet Biosciences	+2.37%	-15.22%	-23.44%	+113.04%	+138.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.1635 of 5 stars	3.5	4.0	0.0	0.8	0.6
FHTX Foghorn Therapeutics	2.3632 of 5 stars	3.6	3.0	0.6	1.7	0.6
LFCR Lifecore Biomedical	0.8339 of 5 stars	1.3	0.0	1.9	4.2	0.6
SGMT Sagimet Biosciences	3.2577 of 5 stars	3.5	4.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	790.65% Upside
FHTX Foghorn Therapeutics	3.17	Buy	$10.67	91.85% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	5.26% Upside
SGMT Sagimet Biosciences	3.00	Buy	$25.67	260.99% Upside

Current Analyst Ratings Breakdown

Latest CABA, SGMT, LFCR, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	SGMT Sagimet Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
8/7/2025	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$29.00
7/24/2025	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.95 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	13.91	N/A	N/A	($1.36) per share	-4.09
LFCR Lifecore Biomedical	$128.87M	2.21	N/A	N/A	$0.04 per share	190.00
SGMT Sagimet Biosciences	$2M	109.03	N/A	N/A	$4.24 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.71	N/A	N/A	N/A	N/A	-92.11%	-74.08%	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	N/A	N/A	N/A	-311.90%	N/A	-28.00%	11/3/2025 (Estimated)
LFCR Lifecore Biomedical	-$38.72M	-$1.31	N/A	N/A	N/A	-31.70%	-846.51%	-13.03%	10/3/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.83	N/A	N/A	N/A	N/A	-39.88%	-38.40%	N/A

Latest CABA, SGMT, LFCR, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	N/A	N/A	N/A	$35.36 million	N/A
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.52	-$0.32	+$0.20	-$0.32	N/A	N/A
8/7/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	-$0.73	-$0.02	-$0.73	$4.17 million	N/A
8/7/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	-$0.10	-$0.01	-$0.06	$35.36 million	$36.44 million
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	4.78	4.78
FHTX Foghorn Therapeutics	N/A	2.62	2.62
LFCR Lifecore Biomedical	113.76	2.84	1.77
SGMT Sagimet Biosciences	N/A	17.55	17.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
FHTX Foghorn Therapeutics	61.55%
LFCR Lifecore Biomedical	83.36%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
FHTX Foghorn Therapeutics	7.58%
LFCR Lifecore Biomedical	32.20%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	91.46 million	81.18 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable
LFCR Lifecore Biomedical	690	37.41 million	25.36 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable

CABA, SGMT, LFCR, and FHTX Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by Brokerages

August 21 at 3:14 AM | marketbeat.com

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

August 20 at 1:01 PM | zacks.com

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

August 20 at 10:36 AM | zacks.com

What is Wedbush's Estimate for SGMT Q2 Earnings?

August 16, 2025 | marketbeat.com

Q2 Earnings Estimate for SGMT Issued By Wedbush

August 16, 2025 | americanbankingnews.com

Sagimet Biosciences Enters New Sales Agreement with Leerink

August 15, 2025 | msn.com

Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025 | finanznachrichten.de

Sagimet Biosciences Tops Q2 EPS Forecast

August 13, 2025 | aol.comA

Sagimet Biosciences Reports Positive Phase 3 Results for Denifanstat in Acne and Initiates Phase 1 Trials for FASN Inhibitors

August 13, 2025 | quiverquant.comQ

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025 | globenewswire.com

Wedbush Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation

August 12, 2025 | msn.com

Wedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT)

August 12, 2025 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Wedbush

August 12, 2025 | americanbankingnews.com

Sagimet Biosciences (SGMT) to Release Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Sagimet Biosciences initiated with an Outperform at Wedbush

August 11, 2025 | msn.com

What is HC Wainwright's Estimate for SGMT Q2 Earnings?

August 11, 2025 | marketbeat.com

Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright

August 8, 2025 | marketbeat.com

Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday

August 6, 2025 | marketbeat.com

Sagimet Biosciences Inc. to Participate in Canaccord Genuity 45th Annual Growth Conference on August 13, 2025

August 5, 2025 | quiverquant.comQ

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by Analysts

July 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, SGMT, LFCR, and FHTX Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.62 +0.02 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 -0.02 (-0.93%)

As of 07:58 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Foghorn Therapeutics NASDAQ:FHTX

$5.56 +0.52 (+10.32%)

Closing price 04:00 PM Eastern

Extended Trading

$5.60 +0.05 (+0.81%)

As of 05:50 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Lifecore Biomedical NASDAQ:LFCR

$7.60 +0.38 (+5.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 0.00 (0.00%)

As of 05:11 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Sagimet Biosciences NASDAQ:SGMT

$7.11 -0.24 (-3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.19 +0.08 (+1.14%)

As of 07:57 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time